5-Amino-1MQ: What It Is and What It Does

What 5-Amino-1MQ is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small quinolinium compound, not a peptide, and sits in this catalog because it is studied alongside metabolic research peptides rather than because it shares their chemistry. It was developed as an inhibitor of NNMT — nicotinamide N-methyltransferase — an enzyme in NAD+ metabolism. Its published literature is genuinely thin: a handful of cell-line and rodent studies, with no human trials. It is supplied as an analytical-grade reference material for in-vitro laboratory research only.

Where it comes from

Interest in NNMT grew as researchers mapped NAD+ metabolism and noticed the enzyme was markedly overexpressed in adipose tissue and in several tumour types. That made it an attractive target, and medicinal-chemistry programmes produced a series of small-molecule inhibitors. 5-Amino-1MQ emerged from that effort as a cell-permeable compound convenient for laboratory use, which is largely why it appears in the research literature at all.

What it does — in plain terms

It inhibits NNMT, an enzyme that methylates nicotinamide and sits within NAD+ salvage metabolism.

How it works

NNMT transfers a methyl group to nicotinamide, consuming a methyl donor and diverting nicotinamide away from NAD+ salvage. Inhibiting the enzyme is therefore studied as a way to influence both cellular NAD+ availability and methyl-group balance. 5-Amino-1MQ is one of the tool compounds used to do that in the laboratory.

Most of the metabolic interest comes from the observation that NNMT is highly expressed in fat tissue, so rodent work has examined what inhibition does to energy metabolism and body-weight change. A separate strand looks at tumour-associated cells, where the enzyme also appears elevated.

It is worth being clear that much of the literature is about NNMT as a target rather than about this specific molecule. Studies naming 5-Amino-1MQ itself are few.

What the research shows

This is the thinnest evidence base of anything in the catalog and it would be misleading to present it otherwise. There are no human trials. The compound-specific work amounts to a small number of cell-line and mouse studies, and a large part of the surrounding literature concerns the NNMT target generally rather than this inhibitor. Treat it as an early-stage research tool.

• Journal of Obstetrics and Gynaecology, 2021 — Reported anti-proliferative activity in HeLa cells for a small-molecule NNMT inhibitor of this class — a cell-line result.
• Scientific Reports, 2022 — In diet-induced-obese mice, combining calorie restriction with NNMT inhibition was associated with a distinct gut microbiome profile.
• Journal for ImmunoTherapy of Cancer, 2024 — Characterised what NNMT does in cancer-associated fibroblasts, establishing why the enzyme is considered a target.
• Drug Discovery Today, 2021 — Reviewed NNMT as an emerging therapeutic target and the state of the inhibitor literature.

What 5-Amino-1MQ is studied for

NAD+ metabolism. NNMT sits in the nicotinamide salvage pathway, so inhibiting it is studied for effects on cellular NAD+ availability and methyl-donor balance.

Adipose-tissue models. The enzyme is highly expressed in fat tissue, which is the origin of the rodent metabolic work — including body-weight change in diet-induced-obese models.

Tumour microenvironment. NNMT is elevated in cancer-associated fibroblasts, and inhibition has been examined in that setting.

Storage & handling

Supplied as a lyophilized powder, 5-Amino-1MQ reference material keeps best cold and dark — refrigerated for short-term storage, frozen for longer. As a small molecule rather than a peptide it is somewhat less fragile than the peptides in this catalog, but the same handling applies once in solution: refrigerate and avoid repeated freeze-thaw.